When US based, direct-to-consumer genetic testing company 23andMe announced last month that it had obtained a patent on a method for determining predisposition to Parkinson’s disease, it highlighted, perhaps inadvertently, a growing area of unresolved tension between clinical, commercial and research interests.
- About
- Projects
- Library
- Bibliography of Bioethics
- Bioethics News
- For Students
- Contacts
- NBNPM
- Advanced Certificate Program
Papildomos nuorodos
